Ruxolitinib has been shown to be superior to best available therapy in the management of steroid refractory or steroid-dependent chronic graft-versus-host disease (cGVHD). Professor Robert Zeiser presented the findings of the REACH 3 study in a session on practice-changing clinical trials at the 62nd ASH Annual Meeting. The open-label, phase 3 study randomised more than ...
JAK inhibitor results not so dramatic for cGVHD: Prof Jeff Szer
By Mardi Chapman
7 Dec 2020